- Home
- BGI vs CLRB Comparison
BGI vs CLRB Comparison
Compare BGI & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGI
- CLRB
- Stock Information
- Founded
- BGI 1879
- CLRB 2002
- Country
- BGI Canada
- CLRB United States
- Employees
- BGI N/A
- CLRB N/A
- Industry
- BGI
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- BGI
- CLRB Health Care
- Exchange
- BGI Nasdaq
- CLRB Nasdaq
- Market Cap
- BGI 15.9M
- CLRB 14.2M
- IPO Year
- BGI 2005
- CLRB N/A
- Fundamental
- Price
- BGI $0.84
- CLRB $4.98
- Analyst Decision
- BGI
- CLRB Hold
- Analyst Count
- BGI 0
- CLRB 2
- Target Price
- BGI N/A
- CLRB N/A
- AVG Volume (30 Days)
- BGI 201.0K
- CLRB 155.1K
- Earning Date
- BGI 07-25-2025
- CLRB 08-14-2025
- Dividend Yield
- BGI N/A
- CLRB N/A
- EPS Growth
- BGI N/A
- CLRB N/A
- EPS
- BGI N/A
- CLRB N/A
- Revenue
- BGI $124,446,731.00
- CLRB N/A
- Revenue This Year
- BGI N/A
- CLRB N/A
- Revenue Next Year
- BGI N/A
- CLRB N/A
- P/E Ratio
- BGI N/A
- CLRB N/A
- Revenue Growth
- BGI N/A
- CLRB N/A
- 52 Week Low
- BGI $0.56
- CLRB $4.11
- 52 Week High
- BGI $2.95
- CLRB $67.50
- Technical
- Relative Strength Index (RSI)
- BGI 65.04
- CLRB 51.74
- Support Level
- BGI $0.64
- CLRB $4.64
- Resistance Level
- BGI $1.07
- CLRB $5.08
- Average True Range (ATR)
- BGI 0.08
- CLRB 0.39
- MACD
- BGI 0.02
- CLRB 0.10
- Stochastic Oscillator
- BGI 46.53
- CLRB 73.11
About BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.